TNF and rheumatoid arthritis: In our study, which included 2,706 RA patients treated with one of three anti-TNF drugs, the most significant finding was restricted to RA patients treated with etanercept (P = 8×10−8), a drug that acts as a soluble receptor to bind circulating cytokine and prevents TNF from binding to its cell surface receptor.